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ABSTRACT 
Objective: To develop simple reverse phase HPLC method for the estimation of Armodafinil in tablet dosage form.  
Methods: Chromatography was performed by isocratic elution on a Stainless steel Hibar C18 column with dimensions 4.6 x 250 mm, packed with 
octadecylsilane bonded to porous silica (C18) with particle size 5 micron. Acetonitrile and water in the ratio of 50:50 v/v is used as mobile phase. 
The flow rate is 1.0 ml/ min and effluent is monitored at 220 nm. Armodafinil was eluted at a retention time of 3.8 minutes. 
Results: The standard curve of Armodafinil was linear over a working range of 1–700 µg/ml and gave an average correlation coefficient of 0.999. 
The limit of quantitation (LOQ) of the drug is 0.1 µg/ ml. Recovery studies were carried out by standard addition method and the recoveries are 
found satisfactory within the range of 99.3 to 101.5 %. The method is precise with % RSD below  
Conclusion: The method is validated in terms of robustness and forced degradation studies were carried out and this method can be applied for 
routine degradation studies ans quantification in regular laboratories.  
Keywords: Armodafinil, RP HPLC, Stability indicating assay, Validation. 
 
INTRODUCTION 
Armodafinil (Figure 1) (2-[(R)-(diphenylmethyl) sulfinyl] 
acetamide) is the R-enantiomer of modafinil, which is a racemic 
mixture of the R- and S-enantiomers. The molecular formula is 
C15H15NO2
 
S and the molecular weight is 273.35. Used in treating 
narcolepsy and shift work sleep disorder (SWSD) and for adjunctive 
treatment of obstructive sleep apnea/ hypopnea syndrome (OSAHS). 
The drug is not official in any of the pharmacopoeia. Literature 
survey revealed that various analytical methods [1-4] were reported 
for determining the racemic mixture containing both R and S forms 
of Modafinil. An electrophoretic method [5] and one LC-MS/MS 
method [6] is reported for determining the R form of Modafinil i. e, 
Armodafinil. The present study focuses on development of simple, 
specific, precise, sensitive and economic stability indicating assay 






Fig. 1: Structure of Armodafinil 
 
MATERIALS AND METHODS 
Reagents and chemicals 
Armodafinil tablets were procured form Orchid Pharma limited, 
Mumbai. Methanol, Acetonitrile, Hydrochloric Acid, Sodium 
Hydroxide are purchased from MERCK.  
Stock solutions and standards 
Stock solution of Armodafinil (1 mg/ml) was prepared by dissolving 
25 mg of Armodafinil in 25 ml of volumetric flask containing 10 ml 
of mobile phase.  
The volume was made up to the mark with mobile phase and the 
solution was sonicated for about 10 min. Working standard 
solutions of Armodafinil were prepared by taking suitable aliquots 
of drug solution from the standard stock solution, 1000µg/ml, and 
the volume was made up to 10 ml with mobile phase. 
Apparatus and chromatographic conditions: 
Quantitative HPLC was performed on Waters HPLC system equipped 
with waters 515 pump and Waters 2489 dual wavelength UV detector. 
Empower2 software is used for data acquisition. A Stainless steel Hibar 
column with dimensions 4.6 x 250 mm, packed with Octadecylsilane 
bonded to porous silica (C18) having particle size 5 micron.  
Method development and optimization  
To develop a suitable HPLC method for the determination of 
Armodafinil, trials were done with different mobile phases, using 
water, buffer(0.5  gm potassium dihydrogen phosphate)and 
acetonitrile in different pH with different compositions of mobile 
phases (40:60, 50:50, 60:40). The method was optimized finally 
using combination of Acetonitrile and water in the ratio of 50/50 
v/v with a flow rate of 1.0 ml/ min. The drug was eluted at retention 
time around 3.8 min with symmetric peak shape. Run time was set 
for 8 minutes. Detection is performed at wavelength 220 nm. 
System suitability  
For performing system suitability studies, 100% test concentration 
under degradation conditions was selected. System suitability test 
was performed by injecting blank solution once and standard 
solution of 100% test concentration six times in to stabilized HPLC 
system. The system suitability was established by evaluating the 
system suitability parameters from the last peak obtained. System 
suitability parameters include retention factor (k’), repeatability, 
resolution (R), tailing factor (T) and theoretical plates (N). It was 
performed by using the concentration of 50µg/ml. The system 
suitability data was given in the table 1  
Assay of Armodafinil marketed formulation 
Twenty tablets of Armodafinil were weighed and powdered 
uniformly using mortar and pestle. An accurately weighed sample of 
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powdered drug containing 25 mg of Armodafinil was dissolved with 
sufficient quantity of mobile phase in a 25 ml volumetric flask. The 
volume was made up to the mark finally using the same. The 
solution is sonicated for 5 minutes. This solution was filtered 
through 0.45 µm filter paper. The solution obtained was diluted with 
mobile phase so as to obtain a required concentration. The 
determinations were carried out in triplicate. The amount of 
Armodafinil present is calculated by comparing with the standard 
solution of Armodafinil. The representative chromatrograms are 
shown in figure 2 & 3. the peak areas were mentioned in the table 2. 
 
Table 2: Assay results of Armodafinil 
S. No. Peak areas 
Standard drug Tablet formulation 
1 6259784 6312897 
2 6265017 6318229 
3 6262995 6053611 
Mean 6262599 6228245 
% Assay 99.4% 
 
 




Fig. 3: chromatogram of Armodafinil test solution 
 
Validation of the assay method [7-9] 
Linearity 
Linearity solutions for assay method were prepared from stock 
solution at concentration levels from 1to 1000µg/ml of analyte 
concentration. The graph of peak area versus concentration was 
plotted by least-squares linear regression analysis. 
The linear fit of the system was illustrated graphically. The linearity 
range was found to be 1 - 700 µg/ml. The samples were assayed 
using the method described above. The standard calibration curve 
for Armodafinil was constructed using the average peak-area versus 
the nominal concentrations of the analyte. Linear least-squares 
regression analysis was performed to assess the linearity.  
Recovery and accuracy 
The accuracy of the assay method was evaluated at five levels, i. e. 
50, 75, 100, 125 and 150% levels (concentrations of 150, 225, 300, 
375 and 450µg/ml respectively) in bulk drug sample. The 
percentages of recoveries were calculated from the slope and Y-
intercept of the calibration curve obtained. Accuracy/recovery 
experiments were performed in triplicate. Accuracy was determined 
by standard addition method. Known amount of different 
concentrations of pure drug solutions were spiked with solution of 
pre analysed formulation of concentration 100 µg/ ml.  
Precision 
The precision was carried out at three levels, intra assay precision of 
injection, intermediate precision and reproducibility.  
Intra assay precision was assessed using 9 determinations covering 
the range of 50,100 and 150% concentration levels of drug solution. 
Intermediate precision (inter day precision) was assessed by 
inducing typical variations like different days and different columns. 
Reproducibility was assessed by different analysts. 
Robustness 
Robustness of the method was studied under degradation conditions 
to study the effects of degradants on Armodafinil in changes method 
conditions. It was carried out by considering deliberate changes in 
detection wavelength, flow rate, mobile phase ratio. Robustness was 
carried out by changing detection wavelength by ±3 nm. Robustness 
was checked by changing the proportion of organic solvent in the 
mobile phase by ±4%. It was also checked for robustness by change 
in flow rate by ±0.2 ml/ min.  
Forced degradation studies 
To study the specificity of the method, pure drug was stressed under 
different degradation conditions. Degradation studies were carried 
out by exposing drug for acid hydrolysis, alkali hydrolysis, oxidative 
degradation, thermal degradation and photolytic degradation. 
Mobile phase is used as solvent for all degradation studies. All the 
solutions for degradation studies were prepared by dissolving 
Armodafinil drug in little amount of mobile phase and the volume 
was made up to the mark with 0.1N HCl, 0.1N NaOH, 1% H2O2. Acid 
hydrolysis is carried out by exposing the drug to 0.1N HCl. Alkali 
hydrolysis is carried out by exposing the bulk drug and powdered 
sample to 0.1N NaOH. Oxidative degradation is carried out by 
exposing the bulk drug to 1% H2O2. Thermal degradation is carried 
out by exposing the bulk drug in Hot air oven at 50 0
Acid degradation 
C. Photolytic 
degradation is carried out by exposing the bulk drug to sun light. 
The degradation studies were carried at a time interval of 15 
minutes. The drug solution was prepared at a concentration of 
100µg/ ml. 
10mg of drug was dissolved in a few ml of mobile phase in a 10 ml 
volumetric flask. The volume was made up to the mark with 0.1N 
HCl, mixed thoroughly and kept aside. After 15, 30 minutes, solution 
was mixed and 1 ml of this solution was pipetted into another 10 ml 
volumetric flask. To this 1 ml solution, 1 ml of 0.1N NaOH was added 
to neutralize the acid and final volume was made upto the mark with 
mobile phase and its peak area was observed by injecting into HPLC. 
Alkali degradation 
10mg of drug was dissolved in a few ml of mobile phase in a 10 ml 
volumetric flask. The volume was made up to the mark with 0.1N 
NaOH, mixed thoroughly and kept aside. After 15, 30 minutes, 
solution was mixed and 1 ml of this solution was pipetted into 
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another 10 ml volumetric flask. To this 1 ml solution, 1 ml of 0.1N 
HCl was added to neutralize the alkali and volume was made up to 
the mark with mobile phase and its peak area was observed by 
injecting into HPLC. 
Photo degradation  
Drug powder was exposed to sunlight. After 15, 30 minutes, 10mg of 
the exposed powder was dissolved in mobile phase in a 10 ml 
volumetric flask. From this solution, 1 ml was pippeted into another 
10 ml volumetric flask and its volume was made upto the mark with 
mobile phase. The peak area of this solution was observed. 
Thermal degradation  
Drug powder was exposed to 500
Linear calibration plot for assay method was obtained over the 
calibration ranges tested, i. e. 1- 700 µg/ml and the correlation 
coefficient obtained was greater than 0.999. The results show that 
an excellent correlation existed between the average peak area and 
concentration of the analyte(Table 3). 
C in a hot air oven. After 15, 30 
minutes, 10mg of the exposed powder was dissolved in mobile 
phase in a 10 ml volumetric flask. From this solution, 1 ml was 
pippeted into another 10 ml volumetric flask and its volume was 
made upto the mark with mobile phase. The peak area of this 
solution was observed. 
Results 
System suitability  
The system suitability of Armodafinil was ascertained good under 
degradation conditions and didn’t show any significant change with 
%RSD less than 2. The degradants peak and Armodafinil peak has 
resolution greater than 2 in all the conditions. This shows no 
interference of degradant peak on Armodafinil peak. The tailing 
factor for Armodafinil was always less than 2.0 with plate count 
more than 2000. 
Linearity 
 
Table 1: System suitability data for Armodafinil 
Retention time (Rt) 3.810 
Peak area 4982685 
USP plate count(N) 4677.0355 
USP tailing factor(T) 1.186 
% RSD of(n= 6) 1.3 
Results of method validation experiments 
 
 
Table 3: Linearity of Armodafinil 
Conc.(µg/ml) Peak Area Conc.(µg/ml) Peak Area 
1 91760 300 12505210 
5 307010 400 16251659 
50 2989697 500 20323095 
100 4837989 600 24402243 
200 8843917 700 28711674 
 
Recovery and accuracy  
The percentage recovery of Armodafinil in bulk drug samples was 
ranged from99.3-101.5 which indicates that the method isaccurate 
(Table 4). 
Precision 
From the results shown in precision Tables5, 6, 7 & 8, it was found 
that pooled and % RSD was less than 2%; which indicates that the 
proposed method has good reproducibility. 
 
Table 4: Accuracy data for Armodafinil 
Spiked 
Levels 













50% 150 9829413 6358316 250 16263079 101.3  
101.5 9698922 6371291 16153903 101.4 
9788409 6318229 16152568 101.9 
75% 225 14928123 6372897 325 21324411 100.5  
100.8 14259859 6214178 20650587 101.6 
14333226 6343288 20660537 100.3 
100% 300 19488942 6325669 400 25776514 100  
100.3 19661406 6213901 26130545 101.5 
19508556 6357126 25743117 99.6 
125% 375 22164423 6153611 475 28395215 100.6  
100.4 23975972 6229245 30391629 101 
23917241 6342612 30170864 99.8 
150% 450 26011432 6139224 550 31665322 98.3  
99.3 27629712 6373759 33829352 99.5 
28262352 6335217 34620376 100.2 
 
Table 5: Intra assay precision data for Armodafinil 
% Level Peak Area Amount Obtained(µg/ml) % Obtained 
 
50 
9530370 152.5 101.7 
9448723 151.3 100.9 
9551190 153 102 
 
100 
18424051 296.1 98.7 
18647226 299.7 99.9 
18817822 302.4 100.8 
 
150 
27536746 442.9 98.4 
27629712 444.4 98.7 
28262352 454.6 101 
 Pooled RSD 1.3 
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Table 6: Intermediate precision data of Armodafinil for day 1 and day 2 
S. No. Day 1 Day 2 
Retention Time Peak Area Retention Time Peak Area 
1 3.810 4982685 3.832 4827119 
2 3.822 5043391 3.869 4975624 
3 3.827 4956253 3.817 4853891 
4 3.832 4959394 3.859 4942266 
5 3.863 4857086 3.846 4931394 
6 3.878 4967299 3.813 4920865 
 % RSD 1.2 % RSD 1.1 
 
Table 7: Intermediate precision data of Armodafinil for Column 1 and Column 2 
S. No. Column 1 Column 2 
Retention Time Peak Area Retention Time Peak Area 
1 3.845 22081819 3.915 22250028 
2 3.848 22129248 3.917 22317532 
3 3.869 21926638 3.919 22317228 
4 3.872 21908561 3.912 22198769 
5 3.874 21882375 3.921 22102983 
6 3.878 22117781 3.917 22043224 
 % RSD 0.5 % RSD 0.5 
 
Table 8: Reproducibility data for Armodafinil 
S. No. Analyst 1 Analyst 2 
Retention time Peak area Retention time Peak area 
1 3.901 25458196 3.900 25224810 
2 3.903 25554856 3.903 26154098 
3 3.903 25324321 3.904 25894457 
4 3.904 25592739 3.906 26085712 
5 3.920 25472533 3.906 26071259 
6 3.921 25414751 3.907 25938737 
 % RSD 0.4 % RSD 1.3 
 
Table 9: Robustness data for change in wavelength 
S. No λ max λ -220 nm max λ - 217 nm max - 223 nm 
Retention Time Peak Area Retention Time Peak Area Retention Time Peak Area 
1 3.806 3775757 3.875 3832275 3.798 3603294 
2 3.817 3628570 3.894 3883298 3.807 3461902 
3 3.820 3711842 3.867 3773320 3.812 3543550 
4 3.837 3772145 3.909 3812237 3.829 3598687 
5 3.842 3707342 3.929 3895566 3.834 3538528 
6 3.846 3750440 3.962 3911544 3.838 3578669 
% RSD 1.5 - 1.4 - 1.5 
 
Table 10: Robustness data for change in mobile phase composition 
S. No. Normal MP ACN: -4%; Water: +4% ACN: +4%; Water: -4% 
Retention Time Peak Area Retention Time Peak Area Retention Time Peak Area 
1 3.932 3881751 4.103 3805520 3.852 3893374 
2 3.919 3913373 4.114 3873667 3.892 3885448 
3 3.874 3795148 4.117 3849376 3.879 3845856 
4 3.937 3889966 4.124 3864902 3.895 3818582 
5 3.930 3890511 4.134 3829262 3.869 3868084 
6 3.953 3923926 4.142 3900418 3.881 3901546 
% RSD 1.2 - 0.9 - 0.8 
 
Robustness 
The percent recovery of Armodafinil was good under most 
conditions and didn’t show any significant change when the critical 
parameters were modified under degradation conditions. The 
degradants peak and Armodafinil peak has resolution greater than 2 
in all the conditions. This shows no interference of degradant peak 
on Armodafinil peak. 
 
The tailing factor for Armodafinil was always less than 2.0 with plate 
count more than 2000 and with %RSD less than 2. The component 
was well eluted under all the changes carried out. Considering the 
modifications in the system suitability parameters, as well as 
carrying the experiment at room temperature may conclude that the 
method conditions were robust (Tables 9,10,11). 
 
 
Table 11: Robustness data for change in flowrate 
S. No. Flow rate-1 ml/min Flowrate-0.8 ml/min Flowrate-1.2 ml/min 
Retention Time Peak Area Retention Time Peak Area Retention Time Peak Area 
1 3.816 3966950 4.813 5039838 3.225 3313690 
2 3.806 3915545 4.824 5015856 3.237 3302692 
3 3.821 3985012 4.857 5089164 3.231 3354139 
4 3.822 3969882 4.823 4916595 3.257 3386897 
5 3.832 3966345 4.842 5053443 3.262 3388427 
6 3.863 3993207 4.885 5031944 3.282 3374513 
% RSD 0.7 - 1.2 - 1.1 
USP Plate count 3219.21 - 3528.07 - 3753.59 
USP Resolution 8.613 - 10.495 - 7.997 
USP Tailing 1.108 - 1.112 - 1.129 
 
Table 12: Stability data for Armodafinil 
Days Retention time Peak area % Stability 
1 3.856 7184293 100 
3.979 7169924 99.7 
2 3.981 7140816 99.3 
3.904 7114240 99 
3 3.869 7096528 98.7 
3.884 7053627 98.1 
4 3.882 7025064 97.7 
 
Stability of drug solution: 
The stability was checked by diluting the stock solution to 100µg/ 
ml. It was checked for 4 days at interval of 12 hours under normal 
laboratory conditions (25 ±1 0
Percentage degradation level of 10% was considered for 
degradation studies. Degradant peaks at 1.73 minutes was observed 
by acid hydrolysis, a degradant peak at 1.75 minutes was observed 
by alkali degradation, a degradant peak at 1.48 minutes was 
observed by photolytic degradation and a degradant peak at 1.68 
minutes was observed by thermal degradation. From the results 
obtained (shown in tables 13, 14, 15, 16), it was found that the drug 
is stable for 30 minutes in acidic and basic medium. The drug has 
thermal and photolytic stability for one hour. By the chromatograms 
obtained during the degradation studies it was found that there is no 
interference of the degradant peak with the analyte peak. Hence the 
method is stability indicating. 
C). The drug was stable up to 36 hours 
and has no significant change in analyte composition and peak areas 
(Table 12). 
Forced degradation studies: 
Specificity was studied by exposing the sample solutions to stress 
conditions i. e. 0.1N HCl, 0.1N NaOH, photolytic degradation and 
thermal degradation.  
 
Table 13: Degradation data for Armodafinil in acidic condition 
S. No. Time of Exposure Peak Area of Armodafinil % of Stable Armodafinil % Degraded 
1 0 hour 6783903 100 0 
2 30 min 5445913 80.2 19.8 
3 1 hour 5316242 78.3 21.7 
 
Table 14: Degradation data for Armodafinil in Alkaline condition 
S. No. Time of Exposure Peak Area of Armodafinil % of Stable Armodafinil % Degraded 
1 0 hour 6783903 100 0 
2 30 min 5036633 74.2 25.8 
3 1 hour 4220732 62.2 37.8 
 
Table 15: Photo degradation data for Armodafinil 
S. No. Time of Exposure Peak Area of Armodafinil % of Stable Armodafinil % Degraded 
1 0 hour 6783903 100 0 
2 30 min 6032936 88.9 11.1 
3 1 hour 5851660 86.2 13.8 
 
CONCLUSION 
The proposed method was found to be simple, rapid, sensitive, 
precise, robust and accurate for determination of Armodafinil in 
formulation. The proposed method was very simple as the 
preparation of mobile phase is simpler. The method is very sensitive 
as the LOQ concentration was very low. The method was found 
linear over wide range of concentration. 
The method can be used for routine analysis of Armodafinil in the 
presence of degradants.  
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